Test bank pharmacotherapeutics for advanced practice a prac
mm mm mm mm mm mm mm
tical approach 5th edition by Virginia P. Arcangelo and Peters
mm mm mm mm mm mm mm mm mm
on Chapters 1-56
mm mm
,mmmmmm
mm TABLE OF CONTENT
mm mm
➢ Chapter 1: Issues for the Practitioner in Drug Therapy
mm mm mm mm mm mm mm mm
➢ Chapter 2: Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principl
mm mm mm mm mm mm mm mm
es
➢ Chapter 3: Impact of Drug Interactions and Adverse Events on Therapeutics
mm mm mm mm mm mm mm mm mm mm
➢ Chapter 4: Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactatio
mm mm mm mm mm mm mm mm mm
n
➢ Chapter 5: Pharmacotherapy Principles in Older Adults
mm mm mm mm mm mm
➢ Chapter 6: Principles of Antimicrobial Therapy
mm mm mm mm mm
➢ Chapter 7: Pharmacogenomics
mm mm mm
➢ Chapter 8: The Economics of Pharmacotherapeutics
mm mm mm mm mm
➢ Chapter 9: Principles of Pharmacology in Pain Management
mm mm mm mm mm mm mm
➢ Chapter 10: Pain Management in Opioid Use Disorder (OUD) Patients
mm mm mm mm mm mm mm mm mm
➢ Chapter 11: Cannabis and Pain Management
mm mm mm mm mm
➢ Chapter 12: Dermatitis
mm mm
➢ Chapter 13: Bacterial, Fungal, and Viral Infections of the Skin
mm mm mm mm mm mm mm mm mm mm
➢ Chapter 14: Psoriasis
mm mm
➢ Chapter 15: Acne Vulgaris and Rosacea
mm mm mm mm mm
➢ Chapter 16: Ophthalmic Disorders
mm mm mm
➢ Chapter 17: Otitis Media and Otitis Externa
mm mm mm mm mm mm
➢ Chapter 18: Hypertension
mm mm
➢ Chapter 19: Hyperlipidemia
mm mm
➢ Chapter 20: Chronic Stable Angina and Myocardial Infarction
mm mm mm mm mm mm mm
➢ Chapter 21: Heart Failure
mm mm mm
➢ Chapter 22: Arrhythmias
mm mm
➢ Chapter 23: Respiratory Infections
mm mm mm
➢ Chapter 24: Asthma and Chronic Obstructive Pulmonary Disease
mm mm mm mm mm mm mm
➢ Chapter 25: mm mm m m Gastric, Functional and Inflammatory Bowel Disorders
mm mm mm mm mm
,➢ Chapter 26: Gastroesophageal Reflux Disease and Peptic Ulcer Disease
mm mm mm mm mm mm mm mm
➢ Chapter 27: Liver Diseases
mm mm mm
➢ Chapter 28:
mm m mm m Urinary Tract Infection
mm mm
➢ Chapter 29:
mm m m mm Prostatic Disorders and Erectile Dysfunction
mm mm mm mm
➢ Chapter 30: Overactive Bladder
mm mm mm
➢ Chapter 31: Sexually Transmitted Infections
mm mm mm mm
➢ Chapter 32: Osteoarthritis and Gout
mm mm mm mm
➢ Chapter 33: Osteoporosis
mm mm
➢ Chapter 34: Rheumatoid Arthritis
mm mm mm
➢ Chapter 35: Headaches
mm mm
➢ Chapter 36: Seizure Disorders
mm mm mm
➢ Chapter 37: Alzheimer’s Disease
mm mm mm
➢ Chapter 38: Parkinson Disease
mm mm mm
➢ Chapter 39: Major Depressive Disorder and Bipolar Disorders
mm mm mm mm mm mm mm
➢ Chapter 40: Anxiety Disorders
mm mm mm
➢ Chapter 41: Sleep Disorders
mm mm mm
➢ Chapter 42: Attention Deficit Hyperactivity Disorder
mm mm mm mm mm
➢ Chapter 43: Substance Use Disorders
mm mm mm mm
➢ Chapter 44: Diabetes Mellitus
mm mm mm
➢ Chapter 45: Thyroid and Parathyroid Disorders
mm mm mm mm mm
➢ Chapter 46: Allergies and Allergic Reactions
mm mm mm mm mm
➢ Chapter 47: Human Immunodeficiency Virus
mm mm mm mm
➢ Chapter 48: Organ Transplantation
mm mm mm
➢ Chapter 49: Pharmacotherapy for Select Thromboembolic Disorders
mm mm mm mm mm mm
➢ Chapter 50: Anemias
mm mm
➢ Chapter 51: Immunizations
mm mm
➢ Chapter 52: Smoking Cessation
mm mm mm
➢ Chapter 53: Weight Loss
mm mm mm
➢ Chapter 54: Contraception
mm mm
, ➢ Chapter 55: Menopause
mm mm
➢ Chapter 56: Vaginitis
mm mm
Chapter 1 Issues for the Practitioner in Drug Therapy
mm mm mm mm mm mm mm mm
MULTIPLE CHOICE
mm
1. Nurse practitioner prescriptive authority is regulated by:
mm mm mm mm mm mm
A. The National Council of State Boards of Nursing
mm mm mm mm mm mm mm
B. The U.S. Drug Enforcement Administration
mm mm mm mm
C. The State Board of Nursing for each state
mm mm mm mm mm mm mm
D. The State Board of Pharmacy
mm mm mm mm
Answer: m m C PTS: m m m m 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
mm mm mm mm mm mm mm
A. The National Council of State Boards of Nursing
mm mm mm mm mm mm mm
B. The U.S. Drug Enforcement Administration
mm mm mm mm
C. The State Board of Nursing
mm mm mm mm
D. The State Board of Medical Examiners
mm mm mm mm mm
Answer: m m D PTS: m m m m 1
3. Clinical judgment in prescribing includes:
mm mm mm mm
A. Factoring in the cost to the patient of the medication prescribed
mm mm mm mm mm mm mm mm mm mm
B. Always prescribing the newest medication available for the disease process
mm mm mm mm mm mm mm mm mm
C. Handing out drug samples to poor patients
mm mm mm mm mm mm
D. Prescribing all generic medications to cut costs
mm mm mm mm mm mm
Answer: m m A PTS: m m m m 1
4. Criteria for choosing an effective drug for a disorder include:
mm mm mm mm mm mm mm mm mm
A. Asking the patient what drug they think would work best for them
mm mm mm mm mm mm mm mm mm mm mm
B. Consulting nationally recognized guidelines for disease management
mm mm mm mm mm mm
C. Prescribing medications that are available as samples before writing a prescription
mm mm mm mm mm mm mm mm mm mm
D. Following U.S. Drug Enforcement Administration (DEA) guidelines
mm mm mm mm mm mm
mm for prescribing
mm
Answer: m m B PTS: m m m m 1
5. Nurse practitioner practice may thrive under health-care reform due to:
mm mm mm mm mm mm mm mm mm
A. The demonstrated ability of nurse practitioners to control costs and improve
mm mm mm mm mm mm mm mm mm mm mm
patient outcomes mm
B. The fact that nurse practitioners will be able to practice independently
mm mm mm mm mm mm mm mm mm mm
C. The fact that nurse practitioners will have full reimbursement under healt
mm mm mm mm mm mm mm mm mm mm
h-care reform mm
D. The ability to shift accountability for Medicaid to the state level
mm mm mm mm mm mm mm mm mm mm
Answer: m m A PTS: m m m m 1
mm mm mm mm mm mm mm
tical approach 5th edition by Virginia P. Arcangelo and Peters
mm mm mm mm mm mm mm mm mm
on Chapters 1-56
mm mm
,mmmmmm
mm TABLE OF CONTENT
mm mm
➢ Chapter 1: Issues for the Practitioner in Drug Therapy
mm mm mm mm mm mm mm mm
➢ Chapter 2: Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principl
mm mm mm mm mm mm mm mm
es
➢ Chapter 3: Impact of Drug Interactions and Adverse Events on Therapeutics
mm mm mm mm mm mm mm mm mm mm
➢ Chapter 4: Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactatio
mm mm mm mm mm mm mm mm mm
n
➢ Chapter 5: Pharmacotherapy Principles in Older Adults
mm mm mm mm mm mm
➢ Chapter 6: Principles of Antimicrobial Therapy
mm mm mm mm mm
➢ Chapter 7: Pharmacogenomics
mm mm mm
➢ Chapter 8: The Economics of Pharmacotherapeutics
mm mm mm mm mm
➢ Chapter 9: Principles of Pharmacology in Pain Management
mm mm mm mm mm mm mm
➢ Chapter 10: Pain Management in Opioid Use Disorder (OUD) Patients
mm mm mm mm mm mm mm mm mm
➢ Chapter 11: Cannabis and Pain Management
mm mm mm mm mm
➢ Chapter 12: Dermatitis
mm mm
➢ Chapter 13: Bacterial, Fungal, and Viral Infections of the Skin
mm mm mm mm mm mm mm mm mm mm
➢ Chapter 14: Psoriasis
mm mm
➢ Chapter 15: Acne Vulgaris and Rosacea
mm mm mm mm mm
➢ Chapter 16: Ophthalmic Disorders
mm mm mm
➢ Chapter 17: Otitis Media and Otitis Externa
mm mm mm mm mm mm
➢ Chapter 18: Hypertension
mm mm
➢ Chapter 19: Hyperlipidemia
mm mm
➢ Chapter 20: Chronic Stable Angina and Myocardial Infarction
mm mm mm mm mm mm mm
➢ Chapter 21: Heart Failure
mm mm mm
➢ Chapter 22: Arrhythmias
mm mm
➢ Chapter 23: Respiratory Infections
mm mm mm
➢ Chapter 24: Asthma and Chronic Obstructive Pulmonary Disease
mm mm mm mm mm mm mm
➢ Chapter 25: mm mm m m Gastric, Functional and Inflammatory Bowel Disorders
mm mm mm mm mm
,➢ Chapter 26: Gastroesophageal Reflux Disease and Peptic Ulcer Disease
mm mm mm mm mm mm mm mm
➢ Chapter 27: Liver Diseases
mm mm mm
➢ Chapter 28:
mm m mm m Urinary Tract Infection
mm mm
➢ Chapter 29:
mm m m mm Prostatic Disorders and Erectile Dysfunction
mm mm mm mm
➢ Chapter 30: Overactive Bladder
mm mm mm
➢ Chapter 31: Sexually Transmitted Infections
mm mm mm mm
➢ Chapter 32: Osteoarthritis and Gout
mm mm mm mm
➢ Chapter 33: Osteoporosis
mm mm
➢ Chapter 34: Rheumatoid Arthritis
mm mm mm
➢ Chapter 35: Headaches
mm mm
➢ Chapter 36: Seizure Disorders
mm mm mm
➢ Chapter 37: Alzheimer’s Disease
mm mm mm
➢ Chapter 38: Parkinson Disease
mm mm mm
➢ Chapter 39: Major Depressive Disorder and Bipolar Disorders
mm mm mm mm mm mm mm
➢ Chapter 40: Anxiety Disorders
mm mm mm
➢ Chapter 41: Sleep Disorders
mm mm mm
➢ Chapter 42: Attention Deficit Hyperactivity Disorder
mm mm mm mm mm
➢ Chapter 43: Substance Use Disorders
mm mm mm mm
➢ Chapter 44: Diabetes Mellitus
mm mm mm
➢ Chapter 45: Thyroid and Parathyroid Disorders
mm mm mm mm mm
➢ Chapter 46: Allergies and Allergic Reactions
mm mm mm mm mm
➢ Chapter 47: Human Immunodeficiency Virus
mm mm mm mm
➢ Chapter 48: Organ Transplantation
mm mm mm
➢ Chapter 49: Pharmacotherapy for Select Thromboembolic Disorders
mm mm mm mm mm mm
➢ Chapter 50: Anemias
mm mm
➢ Chapter 51: Immunizations
mm mm
➢ Chapter 52: Smoking Cessation
mm mm mm
➢ Chapter 53: Weight Loss
mm mm mm
➢ Chapter 54: Contraception
mm mm
, ➢ Chapter 55: Menopause
mm mm
➢ Chapter 56: Vaginitis
mm mm
Chapter 1 Issues for the Practitioner in Drug Therapy
mm mm mm mm mm mm mm mm
MULTIPLE CHOICE
mm
1. Nurse practitioner prescriptive authority is regulated by:
mm mm mm mm mm mm
A. The National Council of State Boards of Nursing
mm mm mm mm mm mm mm
B. The U.S. Drug Enforcement Administration
mm mm mm mm
C. The State Board of Nursing for each state
mm mm mm mm mm mm mm
D. The State Board of Pharmacy
mm mm mm mm
Answer: m m C PTS: m m m m 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
mm mm mm mm mm mm mm
A. The National Council of State Boards of Nursing
mm mm mm mm mm mm mm
B. The U.S. Drug Enforcement Administration
mm mm mm mm
C. The State Board of Nursing
mm mm mm mm
D. The State Board of Medical Examiners
mm mm mm mm mm
Answer: m m D PTS: m m m m 1
3. Clinical judgment in prescribing includes:
mm mm mm mm
A. Factoring in the cost to the patient of the medication prescribed
mm mm mm mm mm mm mm mm mm mm
B. Always prescribing the newest medication available for the disease process
mm mm mm mm mm mm mm mm mm
C. Handing out drug samples to poor patients
mm mm mm mm mm mm
D. Prescribing all generic medications to cut costs
mm mm mm mm mm mm
Answer: m m A PTS: m m m m 1
4. Criteria for choosing an effective drug for a disorder include:
mm mm mm mm mm mm mm mm mm
A. Asking the patient what drug they think would work best for them
mm mm mm mm mm mm mm mm mm mm mm
B. Consulting nationally recognized guidelines for disease management
mm mm mm mm mm mm
C. Prescribing medications that are available as samples before writing a prescription
mm mm mm mm mm mm mm mm mm mm
D. Following U.S. Drug Enforcement Administration (DEA) guidelines
mm mm mm mm mm mm
mm for prescribing
mm
Answer: m m B PTS: m m m m 1
5. Nurse practitioner practice may thrive under health-care reform due to:
mm mm mm mm mm mm mm mm mm
A. The demonstrated ability of nurse practitioners to control costs and improve
mm mm mm mm mm mm mm mm mm mm mm
patient outcomes mm
B. The fact that nurse practitioners will be able to practice independently
mm mm mm mm mm mm mm mm mm mm
C. The fact that nurse practitioners will have full reimbursement under healt
mm mm mm mm mm mm mm mm mm mm
h-care reform mm
D. The ability to shift accountability for Medicaid to the state level
mm mm mm mm mm mm mm mm mm mm
Answer: m m A PTS: m m m m 1